Table 5 Inorganic nanoparticles for small nucleic acid drug delivery

From: Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

Inorganic nanoparticle

Organic modification

Disease

Nucleic acid drug

Therapeutic target

Administration route

Ref.

AuNPs

CLPFFD peptide

Perinatal asphyxia

siRNA

PARP-1

Intraperitoneal injection

463

AuNPs

PLL

Spinal cord injury

siRNA

SEMA3A

Lesion site injection

474

MSN

PLR, PEG, AS1411 aptamer

TNBC

siRNA

BCL-2

-

483

MSN

PEI

-

siRNA

COLL1A

Intraperitoneal injection

495

Iron oxide nanorod

RVG-conjugating polymer, dopamine

AD

siRNA

NF-κB

Intravenous injection

504

  1. AuNPs gold nanoparticles, MSN mesoporous silica nanoparticles, PLR poly-L-arginine, TNBC triple-negative breast cancer, PLL Poly-l-lysin, PEI polyethyleneimine, AD Alzheimer’s Disease
Back to article page